Demonstrating Discontent, May 21, 1990

Activists demanded greater access to and involvement in clinical research for AIDS treatments—and their protests were heard.

Written byAndrea Anderson
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

SPEAKING OUT, ACTING UP: AIDS activists from around the country came together to “Storm the NIH” on May 21, 1990, setting off colored smoke bombs en route to buildings where NIH and NIAID directors had their offices. The demonstration “made a huge statement” about activists’ demands for increased patient access to clinical trial decisions, says activist Peter Staley. “The people whose minds were ultimately changed: this action made very clear to them how important this goal was to us.”FLICKR, NIH HISTORY OFFICE

National Institutes of Allergy and Infectious Disease (NIAID) director Anthony Fauci raced down the stairs of Building 31. Roughly 1,000 AIDS activists filled the National Institutes of Health (NIH) campus in Bethesda, Maryland, armed with signs ranging from relatively benign expressions of discontent with the state of AIDS research (“We’re Fired Up”) to attacks directed at Fauci himself (“Fuck You, Fauci”).

Groups split off to perform varied protest actions. Some staged die-ins, lying down across NIH’s lawns as if they were dead. Peter Staley, a member of “AIDS Coalition to Unleash Power” (ACT UP), went for high ground. Flanked by two other activists, he approached building 31 and used his friends’ hands to springboard onto the concrete awning.

Fauci, who had met with Staley and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

July/August 2017

DNA Erector Sets

New blueprints for the double helix

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies